WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005013940) STABLE CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING FENOFIBRATE AND PRAVASTATIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/013940    International Application No.:    PCT/BE2003/000133
Publication Date: 17.02.2005 International Filing Date: 06.08.2003
Chapter 2 Demand Filed:    04.03.2005    
IPC:
A61K 9/20 (2006.01), A61K 9/28 (2006.01), A61K 9/48 (2006.01), A61K 9/50 (2006.01), A61K 31/22 (2006.01), A61K 45/06 (2006.01)
Applicants: GALEPHAR M/F [BE/BE]; Rue du Parc Industriel 39, B-6900 Marche-en-Famenne (BE) (For All Designated States Except US).
VANDERBIST, Francis [BE/BE]; (BE) (For US Only).
BAUDIER, Philippe [FR/BE]; (BE) (For US Only).
DEBOECK, Arthur [BE/US]; (US) (For US Only).
SERENO, Antonio [BE/BE]; (BE) (For US Only)
Inventors: VANDERBIST, Francis; (BE).
BAUDIER, Philippe; (BE).
DEBOECK, Arthur; (US).
SERENO, Antonio; (BE)
Agent: POWIS DE TENBOSSCHE, Roland; Cabinet Bede, Boulevard General Wahis 15, B-1030 Brussels (BE)
Priority Data:
Title (EN) STABLE CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING FENOFIBRATE AND PRAVASTATIN
(FR) COMPOSITIONS PHARMACEUTIQUES STABLES A LIBERATION CONTROLEE CONTENANT DU FENOFIBRATE ET DE LA PRAVASTATINE
Abstract: front page image
(EN)A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterized in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.
(FR)L'invention concerne une composition pharmaceutique à libération contrôlée qui contient une dose efficace de pravastatine et de fénofibrate. Cette composition est caractérisée en ce que la valeur absolue de la différence entre les périodes de concentration maximale (Tmax) de la pravastatine et de l'acide fénofibrique est égale ou supérieure à 1,5 heure après la prise avec des aliments par des humains.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)